Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study introduced a simple and reliable in vitro assay capable of large-scale simultaneous screening of hair growth-promoting compounds using a 3D co-culture system of human dermal papilla and outer root sheath cells.

This study found that valproic acid and crocin, alone or together, significantly increased the expression levels of neurotrophic factors in rat-derived epidermal neural crest stem cells, suggesting therapeutic potential for neurological disorders.

This review discusses the pharmacological properties and clinical applications of cyproterone acetate and similar antiandrogens, noting previous failures in local applications due to concentration limitations; it reports no new empirical results.

This study found that Regenera ActivaAMT significantly improved hair growth and patient satisfaction in both men and women with Androgenetic Alopecia, suggesting it may be an effective alternative to hair transplants.

This review explores the cellular dynamics of graft rejection in vascularized composite allotransplantation and discusses how understanding these processes might lead to innovative treatments for managing rejection.

This review examines compounds that activate IK1 channels, highlighting their potential for developing Kir channel agonists and addressing safety concerns, but does not report new experimental findings.

This study found that non-small-cell lung cancer patients experienced less adverse events with third-generation EGFR-TKIs compared to first and second generations, although fear of cancer progression, anxiety, and depression were still prevalent.

This study found that TNFα inhibitors can induce psoriatic alopecia, highlighting that early diagnosis and discontinuation of the drugs in some cases may prevent irreversible scalp damage.

This review highlights recent advances in pediatric dermatologic treatments, including the use of propranolol for infantile hemangiomas and etanercept for plaque psoriasis, but it reports no new clinical results.

Tacalcitol ointment effectively improves bilateral nevus comedonicus.

This study describes the patterns of clinical response in patients with severe alopecia areata treated with baricitinib over 52 weeks, based on integrated data from two Phase 3 trials.

This study found that treating dogs with benign prostatic hyperplasia using osaterone acetate reduced prostatic volume and increased diffusion times of an ultrasound contrast agent, suggesting effective treatment and potential for CEUS monitoring.

In this study, oral tofacitinib was associated with significant hair regrowth in patients with alopecia areata, achieving over 50% reduction in Severity of Alopecia Tool scores, with mild side effects.

In this study, researchers analyzed adverse events linked to avacopan using FDA data, finding no high-priority safety concerns but identifying five potential new adverse events, including alopecia, primarily among American patients, and noting a higher risk of liver dysfunction in Japanese patients.

This study found that treatment with oral tofacitinib, alone or with other therapies, was associated with clinical improvement in most patients with recalcitrant lichen planopilaris.

This study developed a low-viscosity triamcinolone acetonide serum, used with a derma stamp microneedling device, to improve targeted treatment of alopecia areata, reporting favorable drug solubility, spreadability, and permeation to hair follicles, while maintaining skin safety.

This study found that non-activated platelet-rich plasma from acetylsalicylic acid-treated patients increased inflammatory cytokines, affecting platelet activation and possibly influencing outcomes in PRP therapies.

In this study, 4‐MAPC treatment reduced ventral prostate weight in rats primarily through decreased synthetic activity, with testosterone propionate increasing prostate weight and activity at pharmacologic doses.

This article discusses the paradoxical effects of valproic acid on hair, reporting both drug-induced hair loss and the potential for hair growth when used topically, but presents no original research findings.

In this study, docetaxel combined with prednisone significantly extended survival by about 2.5 months in men with hormone-resistant metastatic prostate cancer compared to mitoxantrone plus prednisone, despite the potential for severe adverse effects.

This study found that treatment with the polyphenolic compound TCQA activated β-catenin, promoting hair regrowth and the initiation of the anagen phase in mice and human dermal papilla cells.

The article concludes that recent legal rulings have strengthened the protection of pharmaceutical patents against generic competition.

This study involving 126 patients found that tofacitinib has high effectiveness and an acceptable safety profile for treating alopecia areata, with a 33.8% complete response rate at 24 weeks and sex as an independent risk factor for outcomes.

In this case report, an elderly woman with erosive pustular dermatosis of the scalp showed complete closure of eroded areas after treatment with prednisone and topical tacrolimus, resulting in stable scarring alopecia.

This study found that RCS-01 cell therapy for aged skin was well tolerated and associated with increased gene expression related to extracellular matrix homeostasis, suggesting potential skin improvement.

In this randomized controlled trial, the nutritional supplement PPT5 α was associated with increased terminal hair percentages and improved self-assessed hair parameters in women with early-stage androgenetic alopecia.

This source discusses using stratum corneum ablation as a promising method to enhance transdermal drug delivery by temporarily removing the skin's outermost barrier to improve medication absorption.

Systemic mastocytosis may cause a type of hair loss called cicatricial alopecia.

This case study reports that a pediatric patient with recalcitrant alopecia areata was treated using a 308 nm excimer lamp and topical tofacitinib 2% gel.

This study found that in patients with frontal fibrosing alopecia, combining topical tacrolimus with isotretinoin is more effective after four weeks of treatment compared to tacrolimus with finasteride, though both regimens offered some benefit.